1
|
Agency for Toxic Substances and Disease
Registry (ATSDR): Toxicological Profile for Lead. ATSDR; Atlanta,
GA: 2007
|
2
|
Steenland K and Boffetta P: Lead and
cancer in humans: Where are we now? Am J Ind Med. 38:295–299. 2000.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Fu H and Boffetta P: Cancer and
occupational exposure to inorganic lead compounds: A meta-analysis
of published data. Occup Environ Med. 52:73–81. 1995. View Article : Google Scholar : PubMed/NCBI
|
4
|
Johnson FM: The genetic effects of
environmental lead. Mutat Res. 410:123–140. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Grover P, Rekhadevi PV, Danadevi K,
Vuyyuri SB, Mahboob M and Rahman MF: Genotoxicity evaluation in
workers occupationally exposed to lead. Int J Hyg Environ Health.
213:99–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Olewińska E, Kasperczyk A, Kapka L,
Kozłowska A, Pawlas N, Dobrakowski M, Birkner E and Kasperczyk S:
Level of DNA damage in lead-exposed workers. Ann Agric Environ Med.
17:231–236. 2010.PubMed/NCBI
|
7
|
Cassini C, Calloni C, Bortolini G, Garcia
SC, Dornelles MA, Henriques JAP, Erdtmann B and Salvador M:
Occupational risk assessment of oxidative stress and genotoxicity
in workers exposed to paints during a working week. Int J Occup Med
Environ Health. 24:308–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kašuba V, Rozgaj R, Milić M, Zeljezić D,
Kopjar N, Pizent A and Kljaković-Gaspić Z: Evaluation of lead
exposure in battery-manufacturing workers with focus on different
biomarkers. J Appl Toxicol. 30:321–328. 2010.PubMed/NCBI
|
9
|
Rapisarda V, Ledda C, Ferrante M, Fiore M,
Cocuzza S, Bracci M and Fenga C: Blood pressure and occupational
exposure to noise and lead (Pb): A cross-sectional study. Toxicol
Ind Health. 32:1729–1736. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Rapisarda V, Ledda C, Castaing M, Proietti
L and Ferrante M: Potential exposure to carcinogens in low-melting
alloys processing. G Ital Med Lav Ergon. 35:73–76. 2013.(In
Italian). PubMed/NCBI
|
11
|
Valentino M, Rapisarda V, Santarelli L,
Bracci M, Scorcelletti M, Di Lorenzo L, Cassano F and Soleo L:
Effect of lead on the levels of some immunoregulatory cytokines in
occupationally exposed workers. Hum Exp Toxicol. 26:551–556. 2007.
View Article : Google Scholar : PubMed/NCBI
|
12
|
International Agency for Research on
Cancer (IARC): IARC Monographs on the Evaluation of Carcinogenic
Risks to Humans: Inorganic and Organic Lead Compounds. 87. WHO
Press; Geneva: 2006
|
13
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Scholl S, Beuzeboc P and Pouillart P:
Targeting HER2 in other tumor types. Ann Oncol. 12:(Suppl 1).
S81–S87. 2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ménard S, Casalini P, Campiglio M, Pupa SM
and Tagliabue E: Role of HER2/neu in tumor progression and therapy.
Cell Mol Life Sci. 61:2965–2978. 2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Mendelsohn J: Blockade of receptors for
growth factors: An anticancer therapy - the fourth annual Joseph H
Burchenal American Association of Cancer Research Clinical Research
Award Lecture. Clin Cancer Res. 6:747–753. 2000.PubMed/NCBI
|
18
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
19
|
Agus DB, Bunn PAJ Jr, Franklin W, Garcia M
and Ozols RF: HER-2/neu as a therapeutic target in non-small cell
lung cancer, prostate cancer, and ovarian cancer. Semin Oncol.
27:(Suppl 11). 53–63; discussion 92–100. 2000.PubMed/NCBI
|
20
|
Cox G, Vyberg M, Melgaard B, Askaa J,
Oster A and OByrne KJ: Herceptest: Her2 expression and gene
amplification in non-small cell lung cancer. Int J Cancer.
92:480–483. 2001. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Hirsch FR, Varella-Garcia M, Franklin WA,
Veve R, Chen L, Helfrich B, Zeng C, Baron A and Bunn PA Jr:
Evaluation of HER-2/neu gene amplification and protein expression
in non-small cell lung carcinomas. Br J Cancer. 86:1449–1456. 2002.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Koeppen HKW, Wright BD, Burt AD, Quirke P,
McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression
of HER2/neu in solid tumours: An immunohistochemical survey.
Histopathology. 38:96–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Calvo BF, Levine AM, Marcos M, Collins QF,
Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, et al:
Human epidermal receptor-2 expression in prostate cancer. Clin
Cancer Res. 9:1087–1097. 2003.PubMed/NCBI
|
24
|
Osman I, Scher HI, Drobnjak M, Verbel D,
Morris M, Agus D, Ross JS and Cordon-Cardo C: HER-2/neu
(p185neu) protein expression in the natural or treated
history of prostate cancer. Clin Cancer Res. 7:2643–2647.
2001.PubMed/NCBI
|
25
|
Santin AD, Bellone S, Roman JJ, McKenney
JK and Pecorelli S: Trastuzumab treatment in patients with advanced
or recurrent endometrial carcinoma overexpressing HER2/neu. Int J
Gynaecol Obstet. 102:128–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Nagy P, Jenei A, Kirsch AK, Szöllosi J,
Damjanovich S and Jovin TM: Activation-dependent clustering of the
erbB2 receptor tyrosine kinase detected by scanning near-field
optical microscopy. J Cell Sci. 112:1733–1741. 1999.PubMed/NCBI
|
27
|
Kaufmann R, Müller P, Hildenbrand G,
Hausmann M and Cremer C: Analysis of Her2/neu membrane protein
clusters in different types of breast cancer cells using
localization microscopy. J Microsc. 242:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Batista BL, Rodrigues JL, Nunes JA, Souza
VC and Barbosa F Jr: Exploiting dynamic reaction cell inductively
coupled plasma mass spectrometry (DRC-ICP-MS) for sequential
determination of trace elements in blood using a dilute-and-shoot
procedure. Anal Chim Acta. 639:13–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
30
|
Lin YW, Chuang SM and Yang JL: Persistent
activation of ERK1/2 by lead acetate increases nucleotide excision
repair synthesis and confers anti-cytotoxicity and
anti-mutagenicity. Carcinogenesis. 24:53–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lu H, Guizzetti M and Costa LG: Inorganic
lead stimulates DNA synthesis in human astrocytoma cells: Role of
protein kinase Cα. J Neurochem. 78:590–599. 2001. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ramesh GT, Manna SK, Aggarwal BB and
Jadhav AL: Lead activates nuclear transcription factor-κB,
activator protein-1, and amino-terminal c-Jun kinase in
pheochromocytoma cells. Toxicol Appl Pharmacol. 155:280–286. 1999.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Wang CY, Lin YW and Yang JL: Activation of
protein kinase Cα signaling prevents cytotoxicity and mutagenicity
following lead acetate in CL3 human lung cancer cells. Toxicology.
250:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
35
|
Jorissen RN, Walker F, Pouliot N, Garrett
TPJ, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
36
|
Markovac J and Goldstein GW: Picomolar
concentrations of lead stimulate brain protein kinase C. Nature.
334:71–73. 1988. View
Article : Google Scholar : PubMed/NCBI
|
37
|
Cho HS, Mason K, Ramyar KX, Stanley AM,
Gabelli SB, Denney DW Jr and Leahy DJ: Structure of the
extracellular region of HER2 alone and in complex with the
Herceptin Fab. Nature. 421:756–760. 2003. View Article : Google Scholar : PubMed/NCBI
|
38
|
Harris RC, Chung E and Coffey RJ: EGF
receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
39
|
Sun X, Tian X, Tomsig JL and Suszkiw JB:
Analysis of differential effects of Pb2+ on protein
kinase C isozymes. Toxicol Appl Pharmacol. 156:40–45. 1999.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Fiddes RJ, Janes PW, Sivertsen SP,
Sutherland RL, Musgrove EA and Daly RJ: Inhibition of the MAP
kinase cascade blocks heregulin-induced cell cycle progression in
T-47D human breast cancer cells. Oncogene. 16:2803–2813. 1998.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Neve RM, Holbro T and Hynes NE: Distinct
roles for phosphoinositide 3-kinase, mitogen-activated protein
kinase and p38 MAPK in mediating cell cycle progression of breast
cancer cells. Oncogene. 21:4567–4576. 2002. View Article : Google Scholar : PubMed/NCBI
|
42
|
Vijapurkar U, Kim MS and Koland JG: Roles
of mitogen-activated protein kinase and phosphoinositide 3-kinase
in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp Cell
Res. 284:291–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
43
|
Ledda C, Loreto C, Zammit C, Marconi A,
Fago L, Matera S, Costanzo V, Fuccio Sanzà G, Palmucci S, Ferrante
M, et al: Non-infective occupational risk factors for
hepatocellular carcinoma: A review (Review). Mol Med Rep.
15:511–533. 2017.PubMed/NCBI
|
44
|
Ledda C and Rapisarda V: Malignant pleural
mesothelioma: The need to move from research to clinical practice.
Arch Med Res. 47:4072016. View Article : Google Scholar : PubMed/NCBI
|
45
|
Ledda C, Loreto C, Matera S, Massimino N,
Cannizzaro E, Musumeci A, Migliore M, Fenga C, Pomara C and
Rapisarda V: Early effects of fluoro-edenite: Correlation between
IL-18 serum levels and pleural and parenchymal abnormalities.
Future Oncol. 12:(23s). 59–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
46
|
Ledda C, Pomara C, Bracci M, Mangano D,
Ricceri V, Musumeci A, Ferrante M, Musumeci G, Loreto C, Fenga C,
et al: Natural carcinogenic fiber and pleural plaques assessment in
a general population: A cross-sectional study. Environ Res.
150:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
47
|
Rapisarda V, Ledda C, Migliore M, Salemi
R, Musumeci A, Bracci M, Marconi A, Loreto C and Libra M: FBLN-3 as
a biomarker of pleural plaques in workers occupationally exposed to
carcinogenic fibers: A pilot study. Future Oncol. 11:(Suppl).
35–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
48
|
Manzella N, Bracci M, Strafella E,
Staffolani S, Ciarapica V, Copertaro A, Rapisarda V, Ledda C, Amati
M, Valentino M, et al: Circadian modulation of 8 oxoguanine DNA
damage repair. Sci Rep. 5:137522015. View Article : Google Scholar : PubMed/NCBI
|
49
|
Rapisarda V, Loreto C, Ledda C, Musumeci
G, Bracci M, Santarelli L, Renis M, Ferrante M and Cardile V:
Cytotoxicity, oxidative stress and genotoxicity induced by glass
fibers on human alveolar epithelial cell line A549. Toxicol In
Vitro. 29:551–557. 2015. View Article : Google Scholar : PubMed/NCBI
|
50
|
Ledda C, Fiore M, Santarelli L, Bracci M,
Mascali G, Dagati MG, Busà A, Ferrante M and Rapisarda V:
Gestational hypertension and organophosphorus pesticide exposure: A
cross sectional study. Biomed Res Int. 2015:2808912015. View Article : Google Scholar : PubMed/NCBI
|
51
|
Rapisarda V, Ledda C, Ricceri V, Arena F,
Musumeci A, Marconi A, Fago L, Bracci M, Santarelli L and Ferrante
M: Detection of pleural plaques in workers exposed to inhalation of
natural fluoro-edenite fibres. Oncol Lett. 9:2046–2052.
2015.PubMed/NCBI
|
52
|
Rapisarda V, Bracci M, Nunnari G, Ferrante
M and Ledda C: Tetanus immunity in construction workers in Italy.
Occup Med (Lond). 64:217–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
53
|
Costa C, Rapisarda V, Catania S, Di Nola
C, Ledda C and Fenga C: Cytokine patterns in greenhouse workers
occupationally exposed to α-cypermethrin: An observational study.
Environ Toxicol Pharmacol. 36:796–800. 2013. View Article : Google Scholar : PubMed/NCBI
|
54
|
Ledda C, Rapisarda V, Bracci M, Proietti
L, Zuccarello M, Fallico R, Fiore M and Ferrante M: Professional
exposure to basaltic rock dust: Assessment by the Vibrio
fischeri ecotoxicological test. J Occup Med Toxicol. 8:232013.
View Article : Google Scholar : PubMed/NCBI
|
55
|
García-Lestón J, Méndez J, Pásaro E and
Laffon B: Genotoxic effects of lead: An updated review (Review).
Environ Int. 36:623–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
56
|
Winder C and Bonin T: The genotoxicity of
lead. Mutat Res. 285:117–124. 1993. View Article : Google Scholar : PubMed/NCBI
|
57
|
Singh Z, Chadha P and Sharma S: Evaluation
of oxidative stress and genotoxicity in battery manufacturing
workers occupationally exposed to lead. Toxicol Int. 20:95–100.
2013. View Article : Google Scholar : PubMed/NCBI
|